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Abstract: Previously, we demonstrated increased calcium levels and synaptic vesicle densities in
the motor axon terminals (MATs) of sporadic amyotrophic lateral sclerosis (ALS) patients. Such
alterations could be conferred to mice with an intraperitoneal injection of sera from these patients
or with purified immunoglobulin G. Later, we confirmed the presence of similar alterations in the
superoxide dismutase 1 G93A transgenic mouse strain model of familial ALS. These consistent
observations suggested that calcium plays a central role in the pathomechanism of ALS. This may
be further reinforced by completing a similar analytical study of the MATs of ALS patients with
identified mutations. However, due to the low yield of muscle biopsy samples containing MATs,
and the low incidence of ALS patients with the identified mutations, these examinations are not
technically feasible. Alternatively, a passive transfer of sera from ALS patients with known mutations
was used, and the MATs of the inoculated mice were tested for alterations in their calcium homeostasis
and synaptic activity. Patients with 11 different ALS-related mutations participated in the study.
Intraperitoneal injection of sera from these patients on two consecutive days resulted in elevated
intracellular calcium levels and increased vesicle densities in the MATs of mice, which is comparable
to the effect of the passive transfer from sporadic patients. Our results support the idea that the
pathomechanism underlying the identical manifestation of the disease with or without identified
mutations is based on a common final pathway, in which increasing calcium levels play a central role.
Keywords: ALS; passive transfer; intracellular calcium; synaptic vesicles; SOD1 mutation;
C9ORF72 mutation
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most common motor neuron diseases, which,
according to the historical principles of neurology, primarily affects the upper and lower motor
neurons [1]. ALS patients are traditionally sorted into two categories. Familial ALS patients represent
5–10% of the patient population, with more than a dozen, mostly autosomal dominant, mutations in
different genes [2,3]. The sporadic form, with no familial accumulation, represents the overwhelming
majority, i.e., 90–95%, of ALS patients [4]. However, the identification of an expansion of the intronic
hexanucleotide repeat sequence in chromosome nine open reading frame 72 (C9ORF72) in patients
with no family history significantly contributed to the decline of the traditional distinction between
sporadic and familial ALS, which have identical clinical manifestations [5]. Since the hexanucleotide
repeat sequence in C9ORF72 is now considered the most frequent genetic alteration, not just in ALS but
in frontotemporal dementia [6], ALS is now considered a multisystem disorder, overlapping mostly
with frontotemporal dementia [7].
In addition, regarding disease manifestations on a continuum of frontotemporal dementia,
ALS blurs the distinction between two specific neurodegenerative diseases. Another noteworthy
observation is that the identified pathomechanisms of ALS are not restricted to this syndrome [8].
Indeed, mechanisms including, but not restricted to, excitotoxicity [9,10], oxidative stress [11–13],
mitochondrial dysfunction [14,15], immune/inflammatory reactions [16–18] and perturbed neuronal
calcium homeostasis [19–23] are shown to contribute to the pathobiology of multiple sclerosis,
Alzheimer’s, Parkinson’s, Huntington’s, and other diseases as well.
ALS plays a distinguished role since, unlike other neurodegenerative diseases affecting the central
nervous system, parts of the degenerating nerve cells can be sampled without the necessity of ethically
questionable brain biopsies. This special anatomical feature [24] provides the opportunity to compare
and validate the results obtained from animal models with appropriate human samples.
It is now accepted that the disturbed calcium homeostasis of affected neurons plays a general role in
neurodegenerative diseases [19], and particularly in ALS, this mechanism may serve as a central factor,
providing positive feedback between the individual components of the complex pathomechanism
of the disease [25]. In our pioneering study with electron microscopic analyses, we described an
elevated calcium level accompanied by an increased number of synaptic vesicles in the motor axon
terminals obtained from sporadic ALS patients [26]. While these results documented for the first time
the perturbed calcium homeostasis in degenerating human nerve cells, the applied sampling was not
uniform, since it was restricted to a subpopulation of ALS patients with sporadic classifications and
no identified mutations. To complete the study and generalize the results, an analysis of the muscle
biopsy samples from patients with identified mutations was required.
Based on our human muscle biopsy study, motor axon terminals could be localized in only 10% of
the 71 patients who underwent a routine biopsy of the biceps muscles in a period of 9 months [26].
In view of these numbers, and because of the low incidence of patients with familial history or identified
mutations, similar examinations are not feasible, since according to the current epidemiological data [27],
the worldwide prevalence of ALS is 4–8 persons/100,000 inhabitants. Thus, such a study would require
a group size of 10 million to provide the same number of patients with a familial history or identified
mutations as in the sporadic study.
An indirect approach to disclose information about the underlying mechanisms in patients with
ALS-related mutations relies on the passive transfer of their blood-derived samples to experimental
animals. Indeed, anomalies, i.e., elevated calcium levels and increased numbers of synaptic vesicles,
observed in the motor axon terminals of sporadic ALS patients, can be transferred to mice inoculated
with whole serum or even with immunoglobulin G (IgG) purified from the blood of these patients [28].
If similar alterations are induced in the blood samples from patients with known mutations (mostly
familial patients), assuming corresponding changes in the donor patients, a coherent view of the
role of calcium in the pathomechanism of ALS could be confirmed. With the present demonstration
that increased calcium can be transferred with the sera from ALS patients with identified mutations,
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data describing increased calcium in the axon terminals of sporadic ALS patients, increased calcium
after passive transfer from sporadic patients and increased calcium in the genetic model of familial
ALS could be obtained (Figure 1).
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Figure 1. Amyotrophic lateral sclerosis (ALS) patients are represented with green circles, and the ALS 
models are symbolized with blue circles. With the passive transfer of serum or immunoglobulin G 
(IgG) from sporadic patients to mice (red arrow), a model of sporadic ALS could be created which 
reproduces the elevated calcium in the motor axon terminals demonstrated in the patients. ALS 
patients are represented with green circles, and the ALS models are symbolized with blue circles. A 
transgenic model of familial ALS, based on the mutations identified in patients, could also be created 
(curved red arrow). By replicating the sporadic ALS model with the passive transfer of sera from 
familial patients (shaded area), another model of familial ALS was set up in the present study. Since 
in each model comparable increases of calcium in the motor axon terminals could be demonstrated 
(green arrows), an elevated calcium level in the motor axon terminals, similar to that seen in sporadic 
patients, could be hypothesized for the familial ALS patients (dashed green arrow). 
Twelve ALS patients with identified mutations, with or without family history (two patients had 
no family history or known mutations) were introduced to the study. Sera prepared from the patients 
were intraperitoneally injected into mice for 2 days with daily injections, then the motor axon 
terminals were analyzed electron microscopically to determine the calcium content and the number 
of synaptic vesicles. The observed increase in calcium levels and the elevated number of synaptic 
vesicles in the axon terminals, together with the previous observations of elevated calcium in the 
genetic model of familial ALS and the passive transfer model of sporadic ALS, provide additional 
data for the concept that elevated calcium levels play a central role in the pathomechanism of ALS. 
This common denominator may contribute to the identical clinical manifestation of the disease in its 
final stage. 
2. Results 
2.1. Ultrastructural Alterations of the Motor Axon Terminals after Inoculation with ALS Sera 
The postsynaptic compartments of the neuromuscular synapses of mice inoculated with sera 
obtained from different ALS patients displayed no structural alterations: intact muscle fibers and 
specialized postsynaptic membranes were visible (Figure 2). Compared to the controls, the most 
obvious alterations of the motor axon terminals of mice injected with sera from ALS patients were 
the increased number of electron-dense deposits (EDDs), representing the distribution of calcium in 
the tissue, and the increased number of synaptic vesicles (Figures 2 and 3). Qualitatively, these 
changes were most prominent in the axon terminals of mice injected with sera from the patient with 
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model of familial ALS, based on the mutations identified in pa ents, could also be cre ted (cu ved red
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(shaded area), anot er mod l of familial ALS was set up in the pr sent study. Since in each model
comparable increases of calcium in the motor axon ter inals c uld be demonstrated (gree arrows),
an elevated calcium level in the motor axon terminals, similar to that seen in sporadic patients, could be
hypothesized for the familial ALS patients (dashed green arrow).
Twelve ALS pati t it identified mutations, with or without family history (two patients
had no family history or known mutations) were introduced to the study. Sera prepared from the
patients were intraperitoneally injected into mice for 2 days with daily injections, then the motor axon
terminals were analyzed electron microscopically to determine the calcium content and the number of
synaptic vesicles. The observed increase in calcium levels and the elevated number of synaptic vesicles
in the axon terminals, together with the previous observations of elevated calcium in the genetic
model of familial ALS and the passive transfer model of sporadic ALS, provide additional data for the
concept that elevated calcium levels play a central role in the pathomechanism of ALS. This common
denominator may contribute to the identical clinical manifestation of the disease in its final stage.
2. Results
2.1. Ultrastructural Alterations of the Motor Axon Terminals after Inoculation with ALS Sera
The postsynaptic compartments of the neuromuscular synapses of mice inoculated with sera
obtained from different ALS patients displayed no structural alterations: intact muscle fibers and
specialized postsynaptic membranes were visible (Figure 2). Compared to the controls, the most obvious
alterations of the motor axon terminals of mice injected with sera from ALS patients were the increased
number of electron-dense deposits (EDDs), representing the distribution of calcium in the tissue,
and the increased number of synaptic vesicles (Figures 2 and 3). Qualitatively, these changes were most
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prominent in the axon terminals of mice injected with sera from the patient with a C9ORF72 mutation
(Figure 2D). Occasionally, swollen mitochondria containing clusters of EDDs were encountered in the
axon terminals of the mice (Figure 2C).
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with superoxide dismutase 1 (SOD1) pAsp90Ala (C) and chromosome 9 open reading frame 72 
(C9ORF72 (D)) mutations, display an increased amount of EDDs (arrows), particularly in (D). 
Furthermore, a global increase in synaptic vesicles can be noted. Occasionally, swollen mitochondria 
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vesicles (arrows) are present. Some of them contain dot-like electron-dense deposits (EDDs). Axon 
terminals from mice injected with serum from ALS patients, represented with superoxide dismutase 
1 (SOD1) pAsp90Ala (C) and chromosome 9 open reading frame 72 (C9ORF72) mutations (D), display 
an increased number of synaptic vesicles in these regions. The increase in the number of synaptic 
vesicles is exceptionally high in the axon terminal of a mouse injected with the sera from a patient 
with a C9ORF72 mutation (D). jf: junctional folds. Scale bar: 200 nm. 
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The intracellular calcium level of motor axon terminals was expressed as the volume occupied 
by the EDDs relative to the volume of the axon terminal. Supporting the qualitative observations, an 
inoculation with all ALS sera induced a significant calcium increase in the axon terminals (superoxide 
dismutase 1 (SOD1) pLeu144Phe: 17.31% ± 0.96%; SOD1 pVal14Met: 17.67% ± 1.96%; SOD1 
pAsp90Ala: 19.37% ± 1.78%; SOD1 pLys91ArgfsTer8: 21.84% ± 1.23%; C9ORF72: 34.29% ± 2.45%; 
sequestosome 1 (SQSTM1) pPro392Leu: 17.30% ± 3.41%; G2/mitotic-specific cyclin F (CCNF) 
Figure 3. Enlarged view of motor axon terminals in the vicinity of the active zones of the neuromuscular
synapses—oxalate-pyroantimonate fixation. In the axon terminal of an untreated mouse (A), and a
mouse injected with serum from a healthy individual (B), only a few synaptic vesicles (arrows) are
present. Some of them contain dot-like electron-dense deposits (EDDs). Axon terminals from mice
injected with serum from ALS patients, represented with superoxide dismutase 1 (SOD1) pAsp90Ala
(C) and chromosome 9 open reading frame 72 (C9ORF72) mutations (D), display an increased number
of synaptic vesicles in these regions. The increase in the number of synaptic vesicles is exceptionally
high in the axon terminal of a mouse injected with the sera from a patient with a C9ORF72 mutation
(D). jf: junctional folds. Scale bar: 200 nm.
2.2. Quantitative Analysis of the Change in the Number of Synaptic Vesicles and Increase in Intracellular
Calcium in Motor Axon Terminals after an Inoculation with ALS Sera
The intracellular calcium level of motor axon terminals was expressed as the volume occupied by
the EDDs relative to the volume of the axon terminal. Supporting the qualitative observations,
an inoculation with all ALS sera induced a significant calcium increase in the axon terminals
(superoxide dismutase 1 (SOD1) pLeu144Phe: 17.31% ± 0.96%; SOD1 pVal14Met: 17.67% ± 1.96%;
SOD1 pAsp90Ala: 19.37% ± 1.78%; SOD1 pLys91ArgfsTer8: 21.84% ± 1.23%; C9ORF72: 34.29% ±
2.45%; sequestosome 1 (SQSTM1) pPro392Leu: 17.30% ± 3.41%; G2/mitotic-specific cyclin F (CCNF)
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pLeu106Val: 21.06% ± 3.68%; NEK1 (NIMA-related kinase 1) and TBK1 (TANK-binding kinase 1):
20.47% ± 3.19%; UBQLN2 (Ubiquilin 2): 17.62% ± 3.42%; sporadic: 23.60% ± 1.37%) compared to the
control groups (untreated: 5.42% ± 0.68%; healthy serum treated: 6.86% ± 1.10% (Figure 4)).
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histochemical method. The data points are split into three main groups: controls, ALS patients and 
ALS outliers, representing the patients with the C9ORF72 mutation. A K-means statistical cluster 
analysis confirmed the presence of these distinct clusters: (i) one represented the untreated mice and 
the healthy volunteers, (ii) another shows all ALS mutations, except the C9ORF72, (iii) and the last 
cluster represented the patients with a C9ORF72 mutation (Figure 6). 
Figure 4. The ratio of the volume of el ctron-dense deposits (ED s) and the volume of the axon
terminals after inoculation with sera from ALS patients. A significant el vation in ED s could be
noted in each amyotr phic lateral sclerosis (ALS) serum treated group. F rthermore, this elevation was
significantly higher (###: p < 0.001) in the motor axon terminals of mice inje ted with sera from ALS
patients with C9ORF72 mutations compared to all other gr ups. Data are repres nted as th mean
value ± standard error of the mean (s.e.m.). Statistical evaluation was determined using a o e-way
analysis of the variance (ANOVA) with the least significant difference post-hoc pairwise comparison.
***: p < 0.001.
To reduce the variability of the results due to the largely inhomogeneous distribution of
synaptic vesicles within the axon terminals, a quantitative evaluation of the density of synaptic
vesicles was limited to the active zones, the physiologically most relevant regions of the synapses.
All treatments with ALS sera resulted in significant increases in the synaptic vesicle density (SOD1
pLeu144Phe: 110.30 ± 8.81 vesicles/µm3; SOD1 pVal14Met: 134.65 ± 1.82 vesicles/µm3; SOD1
pAsp90Ala: 133.87 ± 10.88 vesicles/µm3; SOD1 pLys91ArgfsTer8: 120.28 ± 11.26 vesicles/µm3;
C9ORF72: 201.15 ± 14.29 vesicles/µm3; SQSTM1 pPro392Leu: 108.01 ± 12.74 vesicles/µm3; CCNF
pLeu106Val: 124.60 ± 9.91 vesicles/µm3; NEK1 and TBK1: 162.43 ± 3.19 vesicles/µm3; UBQLN2:
138.55 ± 15.02 vesicles/µm3; sporadic: 116.10 ± 7.68 vesicles/µm3), while there were no significant
changes in the group treated with healthy sera (89.40 ± 6.05 vesicles/µm3) compared to the control
(80.38 ± 1.5 vesicles/µm3 (Figure 5)).
The elevations in the density of the active zone synaptic vesicles and the level of intracellular
calcium were noted as significant effects of the inoculation with sera from ALS patients. Since these
parameters are closely associated with the activity of the synapses, their cross-relation was analyzed
as well (Figure 6). In Figure 6, each point represents patients, except the “untreated control” points,
which display values derived from individual mice, to illustrate the reproducibility of the histochemical
method. The data points are split into three main groups: controls, ALS patients and ALS outliers,
representing the patients with the C9ORF72 mutation. A K-means statistical cluster analysis confirmed
the presence of these distinct clusters: (i) one represented the untreated mice and the healthy volunteers,
(ii) another shows all ALS mutations, except the C9ORF72, (iii) and the last cluster represented the
patients with a C9ORF72 mutation (Figure 6).
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Figure 6. The active zone synaptic vesicle density is plotted against the volume density of the
calcium-containing electron-dense deposits (EDDs). Since all amyotrophic lateral sclerosis (ALS)
sera treatments resulted in a mutual increase in calcium levels and the density of synaptic vesicles,
their combined values could form new groups (blue ellipse) separated from controls (yellow ellipse).
The points representing the patients with the chromosome 9 open reading frame 72 (C9ORF72) mutation
were sorted into a stand-alone cluster (represented by the red ellipse), and this group is beyond the
99.5% confidence regions of the control and the ALS groups represented by the covered area of the
yellow and blue confidence ellipses.
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3. Discussion
Calcium, a ubiquitous second messenger, plays an integral physiological role as summarized by
Otto Loewi in his famous saying “Yes, calcium is everything” (1959). It has also been proposed to play
a role in pathological situations [29]. However, starting from the early 1980s, based on the pioneering
studies of Dennis W. Choi on neocortical cultures [30,31], an autonomous “calcium hypothesis” has
been developed, since, according to his observations, the “toxicity of glutamate on cortical neurons may
depend primarily on the presence of extracellular calcium, probably through a mechanism which is
distinct from simple excitotoxicity” [32]. Nowadays it is widely accepted that increased calcium levels
are a key factor not only in acute injuries [10,33] but also in the pathobiology of neurodegenerative
diseases [19,21,34–37].
The role of calcium in the pathomechanism of different neurodegenerative diseases has been
directly or indirectly evidenced in their models, such as in Alzheimer’s disease [38], Parkinson’s
disease [36], or ALS [39,40]. However, a direct demonstration of altered calcium levels in degenerating
human nerve cells has been hampered due to the absence of brain biopsy samples for calcium studies,
because of evident ethical concerns, and as autopsy samples are not suitable for this purpose since the
fast diffusion of intracellular elements significantly alters their original distribution. ALS, however,
is unique compared to other neurodegenerative diseases, since, due to the anatomy of the motor
system, parts of the degenerating motor neurons residing in the skeletal muscles can be sampled with
routine muscle biopsies [24].
In our original study, based on the results of muscle biopsies obtained from seven sporadic ALS
patients, increased calcium levels and an increased synaptic vesicle number could be demonstrated in
the motor axon terminals. These parameters separated the patients from the control population [26].
Similar alterations could be transferred to mice via inoculation of the total sera or IgG obtained
from these patients [17,28]. In the present experiment, to prove that similar alterations may exist in
the rest of the population of ALS patients, sera from ALS patients with identified mutations were
collected, inoculated into mice, and the motor axon terminals in the hindlimb interosseous muscles
were analyzed. For these experiments, instead of IgG, serum was used for injections, as in our
previous study [17], because it exhibits more complex and stronger biological effects than the isolated
and thus partially inactivated IgG. The degenerative effect of ALS serum partially comes from the
presence of autoimmune IgG antibodies, which were characterized in another study where a panel of
20 IgG antibodies specific for ALS were identified from the sera of ALS patients [41]. Furthermore,
purified IgG can initiate motoneuronal calcium accumulation, as was demonstrated by Pullen and
his coworkers [42,43]. ALS IgG also induced selective motor neuron apoptosis in rat mixed primary
spinal cord cultures [44]. Immunoglobulins from patients with sporadic ALS can bind [45] and alter
the function of L-type and P-type, as well as other neuronal calcium channels [46–49]. These antibodies
induce ultrastructural degeneration in motor neurons and an increase in intracellular calcium [50],
as well as an increase in the frequency of miniature endplate potentials [48] and glutamate levels in
the cerebrospinal fluid [51]. The intraperitoneal administration of IgG from ALS patients and the
immunized goat model of ALS increased TNF-α, IL-6, and IL-10 levels in the spinal cord and the
serum of inoculated mice [52]. The pathomechanistic role of ALS IgG in the sera of the patients
seems to be essential since, if the IgG is removed by pre-incubating it with anti-human IgG or with
the putative target of the antibodies, the pathobiological effects completely vanish [48]. Besides the
effect on motor neurons, the various specific effects of ALS IgG were described in other cell types,
also playing a role in the pathomechanism of ALS. These antibodies are capable of inducing oxidative
stress and an upregulation of the antioxidative system in a BV-2 microglial cell line [53] and also affect
cytosolic calcium homeostasis in cultured rat astrocytes [54]. Nevertheless, sera from two sporadic
ALS patients were also included in the present study, which proved that identical results could be
obtained from these patients as in the previous study. The present results, together with our earlier
findings [26], provide the basis for the assumption that in ALS, regardless of the primary cause of
the disease, calcium plays a central role in the pathomechanism. The increased number of synaptic
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vesicles and the simultaneously elevated levels of intra-terminal calcium are congruent with the needle
electromyography findings in ALS patients with spontaneous and involuntary discharges, which
may arise from the motoneuron or its axon [55]. In vitro, our findings are also compatible with the
physiological abnormality of increased miniature endplate potentials, which are depolarizations of the
postsynaptic terminal caused by the release of a single vesicle into the synaptic cleft, which could be
induced by the passive transfer of IgG [56] or sera [57] from ALS patients.
The present findings demonstrate that, according to the mutual effect of the sera from ALS patients
with known mutations on the number of synaptic vesicles and the level of intracellular calcium,
the patients can be sorted into clusters that differentiate them from the controls (Figure 6). Although
it lies beyond the scope of the present study to analyze the effect of the sera obtained from patients
with different mutations, it is noteworthy that the effect of the sera obtained from patients with the
C9ORF72 mutation exceeds the effect of all other sera from patients with identified mutations (Figure 6).
The extraordinary effect of this mutation might be attributed to both the loss of function of the C9ORF72
protein and toxic gain of function from the C9ORF72 repeat ribonucleic acid (RNA), or from dipeptide
repeat proteins produced by a repeat-associated non-ATG translation [58]. Mutations in this gene
have a strong immune/inflammatory effect due to a generalized systemic pro-inflammatory state,
which initiates autoimmunity-related degenerative pathways and microglia activation in the C9ORF72
knock-out model of ALS [59], without a regression of the motor function [60].
In summary, it should be noted that starting from the original observation that calcium
is indeed elevated in the degenerating nerve cells of humans [26], which can be replicated in
different models of ALS [28,61], several lines of study have been initiated, investigating this
pathobiological process as a possible neuroprotective strategy in ALS. For example, based on the
recognition that certain calcium-binding proteins may lend resistance to neurons [62–64], double
transgenic parvalbumin × mutant SOD1 mice were bred, overexpressing the parvalbumin protein
in spinal motor neurons, which delayed disease onset in the mice, but could not ultimately rescue
them [65]. It was a reasonable assumption that increasing the calcium buffering capacity of the
cells would increase their tolerance, but, per definition, sooner or later saturation occurs if the
stress endures. However, an alternative therapeutic approach was based on reducing the calcium
influx through calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)
receptors, which has a specific alteration in ALS [66]. After some promising results in SOD1 transgenic
mice with the drug Talampanel [67], which was also introduced in clinical trials, it turned out, that its
protective effect against calcium overload was effective only if the treatment was started before the
appearance of clinical symptoms [68]. Our present results confirm the central role of calcium in the
pathomechanism of ALS and probably in other neurodegenerative diseases. This phenomenon may
unify the different pathomechanisms into a self-perpetuating cascade [25] responsible for the identical
clinical manifestation of different forms of ALS, regardless of whether the patients possess mutations
for the disease, which underlines the necessity of early diagnostic markers for effective treatments.
4. Materials and Methods
4.1. Ethics Approval and Consent to Participate
Ethical approvals for the studies involving animals were given by (1) The Government Office in
Csongrád-Csanád County, Hungary; (2) The Committee for Animal Experiments of the University of
Szeged, Szeged, Hungary I. 74-II/2015 (14 January 2015). All experiments were carried out in accordance
with the institutional guidelines for the use and care of experimental animals and the governmental
law for animal protection (XXVIII. chapter IV. paragraph 31) which conforms to international laws and
policies (EEC Council Directive 86/609, OJL 358 1 DEC. 12, 1987; NIH Guide for the Care and Use of
Laboratory Animals, United States National Research Council, revised 1996). All efforts were made to
minimize animal suffering throughout the experiments.
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Ethical approval for obtaining blood from patients and controls, for research purposes, and storing
it anonymously with the written informed consent of patients and controls was given by The Human
Investigation Review Board, University of Szeged, Hungary, in agreement with the declaration of
the Medical World Federation proclaimed in Helsinki 1964. (Project title: Search for Biomarkers in
Neurodegenerative Diseases: Amyotrophic Lateral Sclerosis, Parkinson’s Disease and Alzheimer’s
Disease #2557/2009 (29 June 2009, revised 23 January 2012).
4.2. Patients
Fourteen ALS patients (Table 1) and three healthy controls participated with informed consent in
the study. Five ALS patients possessed mutations in the SOD1 gene. Three patients had a GGGGCC
hexanucleotide repeat expansion in the C9ORF72 gene. One patient had a mutation in the SQSTM1
gene, another one had a mutation in the CCNF gene, a further one had a mutation in the UBQLN2 gene
and finally, a patient with ALS and frontotemporal dementia had a double mutation in the NEK1 gene
together with a mutation in the TBK1 gene (Table 1). Two patients, composing the sporadic ALS group,
were genetically screened for all 35 major ALS genes and proved to be negative (Table 1). For controls,
sera from 3 age-matched healthy volunteers were obtained. Untreated animals also served as controls.
The genomic DNAs were isolated from blood samples. The entire coding region of the SOD1
genes and the flanking introns were amplified and the polymerase chain reaction products underwent
a direct sequencing on an ABI 3100 sequencer (Thermo Scientific; Waltham, MA, USA) and were
compared with the wild-type sequences on the Ensemble Genome Browser [69]. The patients who
carried the GGGGCC repeat expansion were also screened for the “risk” haplotype, the rs3849942
variant, which was used as a marker for the “risk” haplotype for the patient and control genotypes.
Rs3849942 genotyping was based on allelic discrimination assays using TaqMan chemistry (Life
Technologies; Budapest, Hungary) [69]. In patient mfALS 4 in Table 1, the mutation screening revealed
a mutation located in the signal peptide (M24I) together with the SOD1 pLeu144Phe mutations. Patient
mALS 9 with an SQSTM1 mutation, patient mALS 10 with a CCNF mutation, patient mALS 11 with a
UBQLN2 mutation, and patient mALS 12 with a NEK1 mutation, together with TBK1 mutations, were
evaluated. ALS patients screened for 35 major ALS related genes with known mutations were targeted
in next-generation sequencing posteriorly [17].
The diagnoses fulfilled the El Escorial revisited [55] and the Awaji [70] criteria for ALS. The patients
were followed up several times and their disease progressions were recorded with the revised ALS
functional rating scale (ALSFRS-R) [71]. The blood samples taken from the cubital veins were frozen,
partly as whole blood and partly as sera after centrifugation, and stored until use at –80 ◦C. Only patient
mALS12 had frontotemporal dementia. The scores of the Mini-Mental State Examination (MMSE) were
in the normal range, except patient mALS 12 who had progressive frontotemporal dementia (Table 1).
Initial symptoms in four patients with SOD1 mutations appeared as lower extremity weaknesses.
In the fifth one, the initial symptoms involved all of the extremities. The disease in patient mALS 2 had
progressed over 12 years with the mutation of SOD1 pAsp90Ala. The patient with the fast progression
(6 months) had a novel heterozygous mutation (c.275_276delAA, pLys91ArgfsTer8) located in the
fourth exon of the SOD1 gene and led to a frameshift with the insertion of 8 novel amino acids and
the formation of a premature stop codon at the new amino acid position 99. Patient mALS 1 had a
SOD1 mutation together with an angiogenin (ANG) mutation and lived one year after the onset of
symptoms. Patient mfALS 3 and mfALS 4 survived for 2 years and 3 years after the appearance of the
symptoms, respectively. The patients with a C9ORF72 repeat expansion had a short disease course
initiated with bulbar (6, 8 and 12 months). The remaining four patients with genetic alterations also
had a short (6 months) disease course. The two sporadic ALS cases without genetic alterations in the
major ALS genes survived 9 months and 1 year after the diagnosis was established.
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Table 1. Summary of the clinical data of the patients.
Patients
Age at
Onset
(Years)
Duration of
the Disease
at the Study
Initial Symptoms ClinicalSigns ALS FRS-R MMSE Genetic Alteration
Family
History Therapy Other Disease
mALS 1 63 1 year proximal bilateral lowerlimb weakness LMN, UMN 32/48 28/30
SOD1 pVal14 Met
ANG Met24Ile negative
Riluzole, Perindopril,
Aspirin, Piracetam,
Vinpocetine, Nebivolol
atherosclerosis, hypertension
mALS 2 75 12 years bilateral lower limbweakness
LMN, UMN,
B 19/48 29/30 SOD1 pAsp90Ala negative Riluzole
cervical and lumbar
spondylarthrosis,
hyperlipidemia
mfALS 3 29 2 years gait disturbance LMN, UMN 36/48 30/30 SOD1 pLeu144Phe grandmother(fraternal) Riluzole -
mfALS 4 49 3 years distal weakness of lowerlimbs
LMN, UMN,
B, PB 25/48 28/30 SOD1 pLeu144Phe
grandmother
(maternal) Riluzole, Citalopram
depression, lumbar discs’
herniation
mALS 5 67 6 months four limbs weakness B, PB, UMN,LMN 39/48 30/30
SOD1 pLys91Arg fs
Ter8 negative
Riluzole, Atorvastatin,
Valsartan
breast cancer (irradiated 8
years ago),
hypercholesterolemia, cervical
and lumbar discs’ protrusion
mALS 6 68 6 months bilateral peroneal palsy,dysarthria
LMN, B,
UMN 44/48 30/30
C9ORF72 repeat
expansion negative
Alprazolam,
Perindopril, Duloxetine
hyperparathyroidism (cured),
generalized lipomatosis,
osteoporosis, hypertension,
depression
mALS 7 55 1 year dysarthria, dysphagia B, PB, LMN,UMN 37/48 27/30
C9ORF72 repeat
expansion negative Riluzole, L-thyroxin Hashimoto’s thyroiditis
mfALS 8 56 8 months dysarthria, dysphagia B, PB, LMN,UMN 36/48 30/30
C9ORF72 repeat
expansion
mother with
suspected
ALS (not
documented)
Riluzole, L-thyroxin hypothyroidism
mALS 9 54 6 months dyspnea B, PB, LMN,UMN 40/48 30/30 SQSTM1 pPro392Leu negative Valsartan-HCT hypertension
mALS 10 61 6 months UMN, LMN lesions in thelower limbs
LMN, UMN,
B 42/48 30/30 CCNF pLeu106Val negative Valsartan, Riluzole
hypertension, cervical and
lumbar discs’ protrusion
mALS 11 65 6 months four limbs weakness LMN, UMN 43/48 29/30 UBQLN2 pMet392Val negative Riluzole hypertension depression
mALS 12 37 6 months four limbs weakness,dysarthria, cognitive deficit
UMN, LMN,
B, PB 39/48 23/30
NEK1 pSer261His TBK1
pLys631 deletion negative
Riluzole, Perindopril,
Paroxetine
hypertension depression,
frontotemporal dementia
sALS1 71 1 year weakness of the right armand leg (peroneal) UMN, LMN 41/48 28/30 - negative
Piracetam, Diclofenac,
Aspirin, Perindopril,
Isosorbide-mononitrate,
Bisoprolol
hypertension,
hypercholesterolemia,
atherosclerosis, post zoster
neuralgia
sALS2 74 9 months dysarthria, dysphagia B, UMN,LMN 39/48 26/26 - negative
Amlodipine,
Perindopril, Metoprolol,
Atorvastatin, Riluzole
hypertension,
hypercholesterolemia
mALS: ALS with identified mutation; mfALS: familial ALS with identified mutation; sALS: sporadic ALS; LMN: lower motor neuron; UMN: upper motor neuron; B: bulbar; PB:
pseudobulbar; ALSFRS-R: ALS functional rating scale revised; MMSE: Mini-Mental State Examination.
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4.3. Passive Transfer with Human Sera and Tissue Preparation
Altogether, 48 male Balb/c mice, obtained from Charles River Appoints AnimaLab Hungary Kft.
(Vác, Hungary), were injected intraperitoneally with 1 mL/day serum from ALS patients with different
mutations (n = 3) or healthy serum (n = 3) for two days. All animals received sera from the same
patient during the inoculation period. However, animals treated with serum from different patients
with the same mutation (patients mfALS 3 and 4; patient mALS 6, 7 and 8) were pooled together,
since there was no statistical difference between the effect of the sera from different patients with the
same mutation. A similar pooling protocol was applied to animals treated with sera from sporadic
patients (patient sALS 1,2). One group of animals did not receive an injection and was used as the
untreated control (n = 3).
During the two-day inoculation period, animals were housed in plastic cages (5 animals/cage,
at most) in a thermoneutral environment (22 ± 3 ◦C) and 12 h light/dark cycle with access to drinking
water and regular rodent chow ad libitum. Twenty-four hours after the second serum injection, muscle
samples from animals were prepared from the animals for the analytical study of calcium by an electron
microscope, as described originally by Borgers and coworkers [72,73]. The method, as adapted and
regularly tested for the specificity of calcium in our laboratory, ensures a good preservation of the tissue
suitable for electron microscopy and results in the EDDs due to the precipitation of tissue calcium by
the fixative [74–78].
First, animals under terminal anesthesia (avertin; 2,2,2-tribromoethanol, Merck, Darmstadt,
Germany; 240 mg/kg body weight in a 1.0 mL volume i.p.) were transcardially perfused with 90 mM
potassium oxalate (Merck; pH adjusted to 7.4 with KOH) followed by 3% glutaraldehyde (Polysciences
Inc., Warrington, PA, USA; pH adjusted to 7.4 with KOH) containing 90 mM of potassium oxalate
(pH 7.4). The hindlimb interosseus muscles were removed and fixed in the same fixative overnight
(4 ◦C). Specimens were then rinsed in 7.5% sucrose (Molar Chemicals Kft., Budapest, Hungary)
containing 90 mM of potassium oxalate (pH 7.4), postfixed with 2% potassium pyroantimonate (Merck)
+1% osmic acid (Sigma; pH adjusted to 7.4 with acetic acid (Molar Chemicals Kft.)) for 2 h (4 ◦C).
Next, specimens were rinsed in distilled water (pH adjusted to 10 with KOH) for 10 min, dehydrated
in a graded series of ethanol (Molar Chemicals Kft.), processed through propylene oxide (Merck),
and embedded in Durcupan ACM (Merck). Blocks were polymerized for 48 h at 56 ◦C. Semithin (0.3µm)
sections were cut from the blocks on an Ultracut UCT ultramicrotome (Leica, Wetzlar, Germany),
etched [79] and stained [80], and then evaluated under an Eclipse 80i light microscope (Nikon, Tokyo,
Japan) to identify the zones of innervation in the muscles. After trimming the blocks to the appropriate
regions, to avoid personal bias in determining the fields for analysis [81], systematic random sets
of ultrathin sections (50 nm) were prepared. The distance between the sections was set to 15 µm to
circumvent repeated sampling of identical neuromuscular synapses during the collection of electron
microscopic images. Sections were mounted on single-hole formvar coated copper grids (Electron
Microscopy Sciences, Hatfield, PA, USA), contrasted with uranyl acetate (Electron Microscopy Sciences;
2% in 50% ethanol) [82] and lead citrate (Electron Microscopy Sciences; 2% in distilled water) [83].
4.4. Quantification of the Intracellular Calcium Levels in the Motor Axon Terminals
Ultrathin sections were examined using a JEM-1400Flash transmission electron microscope (JEOL,
Tokyo, Japan). Sections from each animal were systematically screened at low magnification (500–2000×)
for the presence of neuromuscular synapses until 15 axon terminals could be collected for microscopic
analysis. Axon terminals were recorded as 16-bit grayscale images at an instrumental magnification of
12,000× with a 2k × 2k high-sensitivity scientific complementary metal-oxide-semiconductor camera
(Matataki Flash sCMOS, JEOL) and saved in a tagged image file format. The relative volume of
the axon terminals occupied by the EDDs representing the calcium precipitates was determined by
point counting methods [84,85], which were modified for these unique structures and photographic
conditions [75]. The recorded pictures were analyzed with the built-in modules of Image-Pro Plus
(Media Cybernetics; Rockville, MD, USA) image analysis software. The tessellation of sampling
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points was superimposed onto each electron microscopic image, then sampling points hitting the
axon terminals in each image served as reference areas and were counted. Sampling points hitting
the EDDs within the reference area were counted as well. The corresponding counts obtained in
the individual fields were summed up throughout the series of the identified axon terminals in each
animal [86]. The appropriate ratios expressing the relative amount of the EDDs within these structures
were calculated for each animal.
4.5. Quantification of the Density of Synaptic Vesicles
In addition to the calcium content in the axon terminals, changes in the synaptic vesicle density in
the active zones were also analyzed and were expressed quantitatively. Electron microscopic images of
15 axon terminals were evaluated for each animal, where all active zones of the neuromuscular junction
were quantified individually. Although the determination of the active zones for these measurements
was arbitrary—by the symmetrical adjustment of a 100 nm wide and 200 nm long rectangle for the
postsynaptic junction—this method was consistently applied during quantification, and adapted from
the analysis of the human motor axon terminals [26]. The volume of the examined region was calculated
using the area of the selected rectangle and the known section thickness. Subsequently, the number
of synaptic vesicles was determined in the created cuboid. Synaptic vesicles were measured if their
center was within the examined volume. Results were averaged per animal, then group averages were
calculated using the individual values of the animals, which were expressed as volume densities.
4.6. Statistical Analysis
To determine the average volume occupied by EDDs within the axon terminals, and the synaptic
vesicle density, the data derived from individual electron microscopic fields were pooled according to
animals and passive transfer groups. Fifteen fields of view for each were analyzed in the motor axon
terminals from each animal. Differences among the multiple means of the volume density of the EDDs
were assessed by a one-way analysis of variance (ANOVA), followed by the least significant difference
post-hoc test. All of the statistical analyses were performed with R (version 3.6.2, R Foundation for
Statistical Computing, Vienna, Austria) and with R Studio Integrated Development Environment
(version 1.1.453, RStudio Inc., Boston, MA, USA) for Windows. All data are presented as mean values
± the standard error of the means (s.e.m.). A cluster analysis was performed using the K-means
clustering algorithm with WEKA data mining software (v3.8.3., Waikato, New Zealand) to investigate
the cross-relationship of the volume density of EDDs and synaptic vesicles in patients with different
ALS genotypes and controls. Since the analysis resulted in distinct clusters, the Jaccard similarity index
was not calculated, but the 99.5% confidence regions of the control and ALS groups were evaluated
and represented in Figure 6 as confidence ellipses.
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Abbreviations
ALS Amyotrophic lateral sclerosis
ALSFRS-R Revised amyotrophic lateral sclerosis functional rating scale
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
ANG Angiogenin
ANOVA Analysis of variance
B Bulbar
C9ORF72 Chromosome 9 open reading frame 72
CCNF G2/mitotic-specific cyclin F
EDDs Electron-dense deposits
IgG Immunoglobulin G
LMN Lower motor neuron
mALS Amyotrophic lateral sclerosis with an identified mutation
mfALS Familial amyotrophic lateral sclerosis with an identified mutation
MMSE Mini-Mental State Examination
NEK1 NIMA-related kinase 1
PB Pseudobulbar
RNA Ribonucleic acid
sALS Sporadic amyotrophic lateral sclerosis
s.e.m. Standard error of the mean
SOD1 Superoxide dismutase 1
SQSTM1 Sequestosome 1
TBK1 TANK-binding kinase 1
UBQLN2 Ubiquilin 2
UMN Upper motor neuron
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Immunoglobulins G from patients with sporadic amyotrophic lateral sclerosis affects cytosolic Ca2+
homeostasis in cultured rat astrocytes. Cell Calcium 2013, 54, 17–25. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 5566 17 of 18
55. Brooks, B.R.; Miller, R.G.; Swash, M.; Munsat, T.L.; World Federation of Neurology Research Group on Motor
Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis.
Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000, 1, 293–299. [CrossRef]
56. Appel, S.H.; Engelhardt, J.I.; García, J.; Stefani, E. Immunoglobulins from animal models of motor neuron
disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities
to the neuromuscular junction. Proc. Natl. Acad. Sci. USA 1991, 88, 647–651. [CrossRef]
57. Mosier, D.R.; Siklós, L.; Appel, S.H. Resistance of extraocular motoneuron terminals to effects of amyotrophic
lateral sclerosis sera. Neurology 2000, 54, 252–255. [CrossRef]
58. Balendra, R.; Isaacs, A.M. C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol.
2018, 14, 544–558. [CrossRef]
59. Lall, D.; Baloh, R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J.
Clin. Investig. 2017, 127, 3250–3258. [CrossRef]
60. Sudria-Lopez, E.; Koppers, M.; de Wit, M.; van der Meer, C.; Westeneng, H.J.; Zundel, C.A.; Youssef, S.A.;
Harkema, L.; de Bruin, A.; Veldink, J.H.; et al. Full ablation of C9orf72 in mice causes immune system-related
pathology and neoplastic events but no motor neuron defects. Acta Neuropathol. 2016, 132, 145–147.
[CrossRef]
61. Siklós, L.; Engelhardt, J.I.; Alexianu, M.E.; Gurney, M.E.; Siddique, T.; Appel, S.H. Intracellular calcium
parallels motoneuron degeneration in SOD-1 mutant mice. J. Neuropathol. Exp. Neurol. 1998, 57, 571–587.
[CrossRef] [PubMed]
62. Lips, M.B.; Keller, B.U. Endogenous calcium buffering in motoneurones of the nucleus hypoglossus from
mouse. J. Physiol. 1998, 511, 105–117. [CrossRef] [PubMed]
63. Palecek, J.; Lips, M.B.; Keller, B.U. Calcium dynamics and buffering in motoneurones of the mouse spinal
cord. J. Physiol. 1999, 520, 485–502. [CrossRef] [PubMed]
64. Vanselow, B.K.; Keller, B.U. Calcium dynamics and buffering in oculomotor neurones from mouse that are
particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease. J. Physiol.
2000, 525, 433–445. [CrossRef] [PubMed]
65. Beers, D.R.; Ho, B.K.; Siklós, L.; Alexianu, M.E.; Mosier, D.R.; Mohamed, A.H.; Otsuka, Y.; Kozovska, M.E.;
McAlhany, R.E.; Smith, R.G.; et al. Parvalbumin overexpression alters immune-mediated increases in
intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis.
J. Neurochem. 2001, 79, 499–509. [CrossRef]
66. Van Den Bosch, L.; Van Damme, P.; Bogaert, E.; Robberecht, W. The role of excitotoxicity in the pathogenesis
of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762, 1068–1082. [CrossRef]
67. Tortarolo, M.; Grignaschi, G.; Calvaresi, N.; Zennaro, E.; Spaltro, G.; Colovic, M.; Fracasso, C.; Guiso, G.;
Elger, B.; Schneider, H.; et al. Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic
mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral
sclerosis-like disease. J. Neurosci. Res. 2006, 83, 134–146. [CrossRef]
68. Paizs, M.; Tortarolo, M.; Bendotti, C.; Engelhardt, J.I.; Siklós, L. Talampanel reduces the level of motoneuronal
calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph. Lateral Scler. Other
Motor Neuron Disord. 2011, 12, 340–344. [CrossRef]
69. Tripolszki, K.; Danis, J.; Padhi, A.K.; Gomes, J.; Bozó, R.; Nagy, Z.F.; Nagy, D.; Klivényi, P.; Engelhardt, J.I.;
Széll, M. Angiogenin mutations in Hungarian patients with amyotrophic lateral sclerosis: Clinical, genetic,
computational, and functional analyses. Brain Behav. 2019, 9, e01293. [CrossRef]
70. Costa, J.; Swash, M.; de Carvalho, M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: A
systematic review. Arch. Neurol. 2012, 69, 1410–1416. [CrossRef]
71. Cedarbaum, J.M.; Stambler, N.; Malta, E.; Fuller, C.; Hilt, D.; Thurmond, B.; Nakanishi, A. The ALSFRS-R: A
revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study
Group (Phase III). J. Neurol. Sci. 1999, 169, 13–21. [CrossRef]
72. Borgers, M.; De Brabander, M.; Van Reempts, J.; Awouters, F.; Jacob, W.A. Intranuclear microtubules in lung
mast cells of guinea pigs in anaphylactic shock. Lab. Investig. 1977, 37, 1–8. [CrossRef] [PubMed]
73. Borgers, M. The role of calcium in the toxicity of the myocardium. Histochem. J. 1981, 13, 839–848. [CrossRef]
[PubMed]
74. Adalbert, R.; Engelhardt, J.I.; Siklós, L. DL-Homocysteic acid application disrupts calcium homeostasis and
induces degeneration of spinal motor neurons in vivo. Acta Neuropathol. 2002, 103, 428–436. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 5566 18 of 18
75. Obál, I.; Engelhardt, J.I.; Siklós, L. Axotomy induces contrasting changes in calcium and calcium-binding
proteins in oculomotor and hypoglossal nuclei of Balb/c mice. J. Comp. Neurol. 2006, 499, 17–32. [CrossRef]
76. Paizs, M.; Engelhardt, J.I.; Katarova, Z.; Siklós, L. Hypoglossal motor neurons display a reduced calcium
increase after axotomy in mice with upregulated parvalbumin. J. Comp. Neurol. 2010, 518, 1946–1961.
[CrossRef]
77. Patai, R.; Paizs, M.; Tortarolo, M.; Bendotti, C.; Obál, I.; Engelhardt, J.I.; Siklós, L. Presymptomatically
applied AMPA receptor antagonist prevents calcium increase in vulnerable type of motor axon terminals of
mice modeling amyotrophic lateral sclerosis. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1739–1748.
[CrossRef]
78. Siklós, L.; Kuhnt, U.; Párducz, A.; Szerdahelyi, P. Intracellular calcium redistribution accompanies changes
in total tissue Na+, K+ and water during the first two hours of in vitro incubation of hippocampal slices.
Neuroscience 1997, 79, 1013–1022. [CrossRef]
79. Maxwell, M.H. Two rapid and simple methods used for the removal of resins from 1.0 micron thick epoxy
sections. J. Microsc. 1978, 112, 253–255. [CrossRef]
80. Richardson, K.C.; Jarett, L.; Finke, E.H. Embedding in epoxy resins for ultrathin sectioning in electron
microscopy. Stain Technol. 1960, 35, 313–323. [CrossRef]
81. Cruz-Orive, L.M.; Weibel, E.R. Sampling designs for stereology. J. Microsc. 1981, 122, 235–257. [CrossRef]
[PubMed]
82. Hayat, M.A. Principles and Techniques of Electron Microscopy: Biological Applications, 4th ed.; Cambridge
University Press: Cambridge, UK, 2000.
83. Reynolds, E.S. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J. Cell
Biol. 1963, 17, 208–212. [CrossRef] [PubMed]
84. Mayhew, T.M. A review of recent advances in stereology for quantifying neural structure. J. Neurocytol. 1992,
21, 313–328. [CrossRef] [PubMed]
85. Weibel, E.R. Stereological Methods Vol. 1. Practical Methods for Biological Morphometry; Academic Press: London,
UK; New York, NY, USA; Toronto, ON, USA; Sydney, Australia; San Francisco, CA, USA, 1979.
86. Domoki, F.; Bari, F.; Nagy, K.; Busija, D.W.; Siklós, L. Diazoxide prevents mitochondrial swelling and Ca2+
accumulation in CA1 pyramidal cells after cerebral ischemia in newborn pigs. Brain Res. 2004, 1019, 97–104.
[CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
